// App-Quantinova.ai

: Cost-Effectiveness of Newly Emerging Regimens for Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Autologous Stem Cell Transplantation (ASCT) Compared with the Current Standards of Care in EU5

Researchers

Presenter

  • John Ashcroft

Principal Investigators

  • Callum Shephard

  • Ashlie Elnoursi

  • Christopher Pelligra

  • Sujith Dhanasiri

Medical Centers

  • Mid Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom

  • Amaris, Toronto, Canada

  • Evidera, Waltham, MA

  • Celgene International Sarl, Boudry, Switzerland

Locations

  • United Kingdom

  • Canada

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Sparsentan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved